SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...

Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit ...

Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...

ORLANDO, Fla. (Ivanhoe Newswire) - Prostate cancer is the second leading cause of death in men right behind heart disease. Patients with this cancer often don’t find out until the disease has advanced ...

GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant ...

ArteraAI Prostate is now an FDA-regulated software (as a medical device) to estimate long-term outcomes and predict the benefit of hormone therapy for individual patients with localized prostate ...

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...

Veracyte specializes in advanced genomic testing for cancer diagnosis and treatment guidance. Its main business is providing diagnostic tests that help clinicians more accurately diagnose and manage ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

Source: Getty Images Investigators analyzed exfoliated cells in urine specimens to identify 50 candidate RNAs for prostate cancer detection. Serum PSA testing is not specific to prostate cancer, and ...